Although job-cut announcements have become a part of daily life in the industry, average salaries have risen to an all-time high. Not only that, job satisfaction is up in pharma. However, this doesn't seem to prevent more people than ever looking to move, finds James Chase
Getting two unique agency cultures to click is no simple task. Larry Dobrow examines four healthcare-agency unions and finds that marital bliss is possible
Sometimes it's a lateral move. Other times, advancing takes fancy footwork. The main thing, say these six biopharma execs, is to think on your feet. As told to Marc Iskowitz
The job cuts haven't stopped. But here's the good news: average salaries are up, job satisfaction is holding steady, and execs seem to be valuing corporate culture over paycheck size. James Chase reports
What if analytics could help predict when one of your staffers needs a growth test, a new career-path option or just some coaching? Tanya Lewis talks with agencies that apply data proactively to develop people
Seek the next rung. Take the plunge. Most of all, these eight senior healthcare execs advise, enjoy the ride. As told to Marc Iskowitz
Despite the job cuts that have darkened the pharma job market, top talent will always be in demand—and most respondents to MM&M's 25th Career & Salary Survey seem fairly content. James Chase reports
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.